|
|
Volumn 13, Issue 2 II, 2007, Pages
|
|
Protein expression profiles in renal cell carcinoma: Staging, prognosis, and patient selection for clinical trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADJUVANT;
EVEROLIMUS;
FORMALDEHYDE;
HYPOXIA INDUCIBLE FACTOR 1ALPHA;
HYPOXIA INDUCIBLE FACTOR 1BETA;
INTERLEUKIN 2;
MAMMALIAN TARGET OF RAPAMYCIN;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
PARAFFIN;
ACCURACY;
CANCER GROWTH;
CANCER IMMUNOTHERAPY;
CANCER RADIOTHERAPY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONFERENCE PAPER;
COUNSELING;
DOSE RESPONSE;
DRUG EFFECT;
FOLLOW UP;
HEALTH STATUS;
HISTOPATHOLOGY;
HUMAN;
IMMUNOHISTOCHEMISTRY;
KIDNEY CARCINOMA;
NEPHRECTOMY;
PATIENT SELECTION;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
TISSUE MICROARRAY;
TREATMENT RESPONSE;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS;
GENE EXPRESSION PROFILING;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
HYPOXIA-INDUCIBLE FACTOR 1;
IMMUNOHISTOCHEMISTRY;
KIDNEY NEOPLASMS;
MODELS, BIOLOGICAL;
PROGNOSIS;
PROTEIN KINASES;
RESEARCH DESIGN;
|
|
EID: 33846853717
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: 10.1158/1078-0432.CCR-06-1864 Document Type: Conference Paper |
|
Times cited : (33)
|
|
References (0)
|
